CGEM Q1 2024 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

Q1 2024 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

-$76,000

Operating Income

-$43M

Net Income

-$37M

EPS (Diluted)

$-0.86

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$449M

Total Liabilities

$24M

Stockholders' Equity

$426M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$76,000	$0	—
Operating Income	-$43M	-$63M	+31.5%
Net Income	-$37M	-$58M	+35.9%